Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90089


Purpose:

The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.


Study summary:

Recent epidemiological studies have demonstrated that the presence of methicillin-resistant Staphylococcus aureus (MRSA) in the airways of patients with CF is associated with more rapid lung function decline and a higher mortality. Tedizolid is a new antibiotic with potent activity against MRSA. Tedizolid is currently FDA approved for treatment of skin soft tissue infections with MRSA. The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with CF.


Criteria:

Inclusion Criteria: - Diagnosis of CF based on positive sweat chloride or known CF mutation - Age > 17 years - Able to spontaneously expectorate sputum Exclusion Criteria: - Any clinically significant laboratory abnormalities - Presence of an ongoing acute pulmonary exacerbation - Pregnancy - Serious past allergy to linezolid or tedizolid - No alcohol, nicotine, or caffeine-containing products during the study period


NCT ID:

NCT02444234


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90089
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.